{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:28:17Z","timestamp":1773696497093,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Post-synaptic dopamine receptor supersensitivity (DARSS) has been extensively researched by Dr. Masaya Segawa, who has investigated the efficacy of very-low-dose levodopa therapy (VLDT; 0.5\u20131 mg\/kg\/day). Considerable Japanese research supports the possibility that VLDT could be used to treat pediatric neurological disorders. We conducted an on-line survey in 2014 to collect real-world data on the use of VLDT to treat DARSS.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A two-step survey, including a screening test and questionnaire, was posted on a private internet site that could be accessed via the VLDT Research Group home page, and 1,165 pediatric neurologists across Japan were invited to complete it.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 25 respondents reported prescribing VLDT; 19 used VLDT to treat autism spectrum disorder, 14 for tics, 12 for speech delay, 9 for Rett syndrome, 7 for attention-deficit\/hyperactivity disorder, intellectual disability, and 6 for sleep problems. Twelve respondents reported prescribing a dose of 0.5 mg\/kg. Twenty-two reported that VLDT was effective for treating behavioral problems, and twenty reported a good efficacy for treating motor symptoms. Adverse events had a low incidence. Notably, respondents chose VLDT for its possible action in DARSS and for its safety. VLDT was commonly used for behavioral problems in patients younger than 5 years, and for motor symptoms in aged 5\u20139 years.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> VLDT could safely treat behavioral and motor symptoms in pediatric neurological disorders. In contrast, dopamine antagonists are associated with potent efficacy, but with adverse effects such as sleepiness and obesity. Further surveys should be conducted with a broader participants.<\/jats:p>","DOI":"10.3389\/fped.2021.569594","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T08:07:10Z","timestamp":1614845230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Very-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan"],"prefix":"10.3389","volume":"9","author":[{"given":"Kyoko","family":"Hoshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asayo","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazue","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Nezu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Yasuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol Scand Suppl."},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-201X.1971.tb10999.x","article-title":"Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol Scand Suppl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/syn.890100304","article-title":"Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation","volume":"10","author":"Hu","year":"1992","journal-title":"Synapse."},{"key":"B4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF03033804","article-title":"Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability","volume":"14","author":"Kostrzewa","year":"2008","journal-title":"Neurotox Res."},{"key":"B5","first-page":"281","article-title":"Age related occurrence of symptoms of infantile autism - clinical and experimental studies (in Japanese)","volume-title":"Ministry of Health, Research on Physical and Mental Disorders \u2018A Comprehensive Study on Family Health and Growth, Development of Children'","author":"Segawa","year":"1988"},{"key":"B6","first-page":"135","article-title":"Catecholamine metabolism in a neurological disease in childhood","volume-title":"Topics in Child Neurology","author":"Segawa","year":"1982"},{"key":"B7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0387-7604(86)80072-9","article-title":"Polysomnography\u2013functional topographical examination of the basal ganglia","volume":"8","author":"Segawa","year":"1986","journal-title":"Brain Dev."},{"key":"B8","first-page":"367","article-title":"Hereditary progressive dystonia with marked diurnal fluctuation\u2013consideration on its pathophysiology based on the characteristics of clinical and polysomnographical findings","volume":"50","author":"Segawa","year":"1988","journal-title":"Adv Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.braindev.2010.10.015","article-title":"Hereditary progressive dystonia with marked diurnal fluctuation","volume":"33","author":"Segawa","year":"2011","journal-title":"Brain Dev."},{"key":"B10","first-page":"331","article-title":"Epileptic seizure with rotational behavior in tuberous sclerosis-pathophysiological consideration","volume":"37","author":"Tanaka","year":"1983","journal-title":"Folia Psychiatr Neurol Jpn."},{"key":"B11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1440-1819.1991.tb02493.x","article-title":"Roles of a subependymal nodule of tuberous sclerosis on pathophysiology of epilepsy","volume":"45","author":"Nezu","year":"1991","journal-title":"Jpn J Psychiatry Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0387-7604(12)80178-1","article-title":"The pathophysiology of the Rett syndrome from the standpoint of polysomnography","volume":"12","author":"Segawa","year":"1990","journal-title":"Brain Dev."},{"key":"B13","first-page":"51","article-title":"[Low-dose levodopa therapy of autistic disorder: evaluation of clinical effectiveness]","volume":"30","author":"Sugiyama","year":"1998","journal-title":"No To Hattatsu."},{"key":"B14","first-page":"55","article-title":"[Low dose L-dopa therapy and SST improved communication skill in a female autistic child]","volume":"47","author":"Arai","year":"2015","journal-title":"No To Hattatsu."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0387-7604(03)90007-6","article-title":"Neurology of Tourette's syndrome (TS) TS as a developmental dopamine disorder: a hypothesis","volume":"25","author":"Nomura","year":"2003","journal-title":"Brain Dev."},{"key":"B16","first-page":"S46","article-title":"Polysomnography in the Rett syndrome","volume":"14","author":"Segawa","year":"1992","journal-title":"Brain Dev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.braindev.2009.09.008","article-title":"Low-dose levodopa is effective for laryngeal dystonia in Xeroderma Pigmentosum Group A","volume":"32","author":"Miyata","year":"2010","journal-title":"Brain Dev."},{"key":"B18","unstructured":"2020"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1139\/o67-185","article-title":"Some characteristics of brain tyrosine hydroxylase","volume":"45","author":"McGeer","year":"1967","journal-title":"Can J Biochem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1046\/j.1471-4159.2003.02017.x","article-title":"Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum","volume":"87","author":"Haycock","year":"2003","journal-title":"J Neurochem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0014-2999(94)90601-7","article-title":"Age-dependent differences in the rate of recovery of striatal dopamine D1 and D2 receptors after inactivation with EEDQ","volume":"252","author":"Crawford","year":"1994","journal-title":"Eur J Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.braindev.2014.11.005","article-title":"Tourette syndrome: update","volume":"37","author":"Hallett","year":"2015","journal-title":"Brain Dev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fped.2020.00083","article-title":"Clinical and genetic heterogeneity in a cohort of chinese children with dopa-responsive dystonia","volume":"8","author":"Chen","year":"2020","journal-title":"Front Pediatr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","article-title":"Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation","volume":"21","author":"Garcia-Borreguero","year":"2016","journal-title":"Sleep Med."},{"key":"B25","article-title":"Clinical Features of Pediatric Restless Leg Syndrome (RLS)","volume-title":"14th Asian and Oceanian Congress of Child Neurology","author":"Nagao","year":"2017"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","article-title":"Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British association for psychopharmacology","volume":"32","author":"Howes","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s10578-016-0704-x","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study","volume":"48","author":"Ichikawa","year":"2017","journal-title":"Child Psychiatry Hum Dev."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.569594\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T08:07:33Z","timestamp":1614845253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.569594\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":27,"alternative-id":["10.3389\/fped.2021.569594"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.569594","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"article-number":"569594"}}